OBJECTIVES: Sustained optimal use of combination antiretroviral therapy (cART) has been shown to decrease morbidity, mortality and HIV transmission. However, incomplete adherence and treatment interruption (TI) remain challenges to the full realization of the promise of cART. We estimated trends and predictors of treatment interruption and resumption among individuals in the Canadian Observational Cohort (CANOC) collaboration. METHODS: cART-naïve individuals ≥ 18 years of age who initiated cART between 2000 and 2011 were included in the study. We defined TIs as ≥ 90 consecutive days off cART. We used descriptive analyses to study TI trends over time and Cox regression to identify factors predicting time to first TI and time to treatment resumption after a first TI. RESULTS: A total of 7633 participants were eligible for inclusion in the study, of whom 1860 (24.5%) experienced a TI. The prevalence of TI in the first calendar year of cART decreased by half over the study period. Our analyses highlighted a higher risk of TI among women [adjusted hazard ratio (aHR) 1.59; 95% confidence interval (CI) 1.33-1.92], younger individuals (aHR 1.27; 95% CI 1.15-1.37 per decade increase), earlier treatment initiators (CD4 count ≥ 350 vs. <200 cells/μL: aHR 1.46; 95% CI 1.17-1.81), Aboriginal participants (aHR 1.67; 95% CI 1.27-2.20), injecting drug users (aHR 1.43; 95% CI 1.09-1.89) and users of zidovudine vs. tenofovir in the initial cART regimen (aHR 2.47; 95% CI 1.92-3.20). Conversely, factors predicting treatment resumption were male sex, older age, and a CD4 cell count <200 cells/μL at cART initiation. CONCLUSIONS: Despite significant improvements in cART since its advent, our results demonstrate that TIs remain relatively prevalent. Strategies to support continuous HIV treatment are needed to maximize the benefits of cART.
OBJECTIVES: Sustained optimal use of combination antiretroviral therapy (cART) has been shown to decrease morbidity, mortality and HIV transmission. However, incomplete adherence and treatment interruption (TI) remain challenges to the full realization of the promise of cART. We estimated trends and predictors of treatment interruption and resumption among individuals in the Canadian Observational Cohort (CANOC) collaboration. METHODS: cART-naïve individuals ≥ 18 years of age who initiated cART between 2000 and 2011 were included in the study. We defined TIs as ≥ 90 consecutive days off cART. We used descriptive analyses to study TI trends over time and Cox regression to identify factors predicting time to first TI and time to treatment resumption after a first TI. RESULTS: A total of 7633 participants were eligible for inclusion in the study, of whom 1860 (24.5%) experienced a TI. The prevalence of TI in the first calendar year of cART decreased by half over the study period. Our analyses highlighted a higher risk of TI among women [adjusted hazard ratio (aHR) 1.59; 95% confidence interval (CI) 1.33-1.92], younger individuals (aHR 1.27; 95% CI 1.15-1.37 per decade increase), earlier treatment initiators (CD4 count ≥ 350 vs. <200 cells/μL: aHR 1.46; 95% CI 1.17-1.81), Aboriginal participants (aHR 1.67; 95% CI 1.27-2.20), injecting drug users (aHR 1.43; 95% CI 1.09-1.89) and users of zidovudine vs. tenofovir in the initial cART regimen (aHR 2.47; 95% CI 1.92-3.20). Conversely, factors predicting treatment resumption were male sex, older age, and a CD4 cell count <200 cells/μL at cART initiation. CONCLUSIONS: Despite significant improvements in cART since its advent, our results demonstrate that TIs remain relatively prevalent. Strategies to support continuous HIV treatment are needed to maximize the benefits of cART.
Authors: V Miller; C Sabin; K Hertogs; S Bloor; J Martinez-Picado; R D'Aquila; B Larder; T Lutz; P Gute; E Weidmann; H Rabenau; A Phillips; S Staszewski Journal: AIDS Date: 2000-12-22 Impact factor: 4.177
Authors: E N van Roon; J M Verzijl; J R Juttmann; A W Lenderink; M J Blans; A C Egberts Journal: J Acquir Immune Defic Syndr Hum Retrovirol Date: 1999-03-01
Authors: Viviane D Lima; Richard Harrigan; David R Bangsberg; Robert S Hogg; Robert Gross; Benita Yip; Julio S G Montaner Journal: J Acquir Immune Defic Syndr Date: 2009-04-15 Impact factor: 3.731
Authors: Loveleen Bansi-Matharu; Gabriela Rodriguez Loria; Stephen R Cole; Henry Mugerwa; Isabel Vecino; Jens Lundgren; Piotr Pulik; Colette Smith; Andrew N Phillips Journal: AIDS Date: 2019-07-01 Impact factor: 4.177
Authors: Linwei Wang; Jeong Eun Min; Xiao Zang; Paul Sereda; Richard P Harrigan; Julio S G Montaner; Bohdan Nosyk Journal: Clin Infect Dis Date: 2017-10-16 Impact factor: 9.079
Authors: James H McMahon; Tim Spelman; Nathan Ford; Jane Greig; Anita Mesic; Charles Ssonko; Esther C Casas; Daniel P O'Brien Journal: AIDS Res Ther Date: 2016-07-11 Impact factor: 2.250
Authors: Glenn-Milo Santos; Benjamin Ackerman; Amrita Rao; Sara Wallach; George Ayala; Erik Lamontage; Alex Garner; Ian W Holloway; Sonya Arreola; Vince Silenzio; Susanne Strömdahl; Louis Yu; Carol Strong; Tyler Adamson; Anna Yakusik; Tran Thu Doan; Poyao Huang; Damiano Cerasuolo; Amie Bishop; Teymur Noori; Anastasia Pharris; Max Aung; Masoud Dara; Ssu Yu Chung; Marguerite Hanley; Stefan Baral; Chris Beyrer; Sean Howell Journal: AIDS Behav Date: 2021-02